Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 22, Issue 3, Pages 289-298
Publisher
Bioscientifica
Online
2015-03-14
DOI
10.1530/erc-15-0075
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gastroenteropancreatic high-grade neuroendocrine carcinoma
- (2014) Halfdan Sorbye et al. CANCER
- Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
- (2014) Tomohiro Yamaguchi et al. CANCER SCIENCE
- Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
- (2014) Ingrid Holst Olsen et al. Journal of Cancer
- Are G3 ENETS neuroendocrine neoplasms heterogeneous?
- (2013) Fritz-Line Vélayoudom-Céphise et al. ENDOCRINE-RELATED CANCER
- FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3
- (2012) O Hentic et al. ENDOCRINE-RELATED CANCER
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
- (2012) Marianne Pavel et al. NEUROENDOCRINOLOGY
- Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
- (2012) Kenichi Sugihara et al. Cancer Medicine
- Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy
- (2011) Staffan Welin et al. CANCER
- Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma
- (2011) Natsuko Tsuda Okita et al. Gastric Cancer
- Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors
- (2011) Jonathan R. Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression
- (2011) Francesco Panzuto et al. JOURNAL OF CLINICAL ONCOLOGY
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) M. Sorensen et al. ANNALS OF ONCOLOGY
- Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients
- (2010) Aldo Scarpa et al. MODERN PATHOLOGY
- A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors
- (2008) C. Theodore et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started